ASTRO Guideline on Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma
Published: September-October 2022 (Web posted June 2022)
This new guideline addresses the management of adult patients with IDH-mutant grade 2 and grade 3 diffuse glioma (as defined by WHO 2021 classification) which includes astrocytoma, IDH-mutant, WHO grade 2; astrocytoma, IDH-mutant, WHO grade 3; oligodendroglioma, IDH-mutant, 1p/19q codeleted, WHO grade 2; and oligodendroglioma, IDH-mutant, 1p/19q codeleted, WHO grade 3.
Developed in collaboration with:
- American Association of Neurological Surgeons/Congress of Neurological Surgeons
- American Association of Neuropathologists
- American Society of Clinical Oncology
- Society for Neuro-Oncology
Endorsed by:
- Society for Neuro-Oncology
- Canadian Association of Radiation Oncology
- European Society for Radiotherapy and Oncology
- Royal Australian and New Zealand College of Radiologists
Resources:
- Guideline slide set
- Press release
- Podcast (featuring the guideline chairs)
- Patient website on brain tumors
- Patient brochure on brain tumors
